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Parapelvic kidney cysts: A distinguishing feature with high
prevalence in Fabry disease.
Backgound. Fabry disease is an X-linked generalized pro-
gressive debilitating lysosomal storage disorder. The disease
usually manifests in childhood, but the diagnosis is often made
following the occurrence of late-stage complications such as
progressive kidney failure. In order to identify key novel re-
nal diagnostic imaging features of Fabry disease, we conducted
a cross sectional case-control study of kidney involvement in
patients with Fabry disease.
Methods. Twenty-four patients (mean age 36.1 ± 8.1 years,
median 37 years, range 20 to 48 years) with chronic neuropathic
pain who were enrolled in an enzyme replacement trial un-
derwent prospective renal imaging evaluation with magnetic
resonance imaging (MRI) and computed tomography (CT) at
the National Institutes of Health, Bethesda, Maryland. We con-
currently enrolled 19 age-matched healthy controls (mean age
34.6 ± 12.0 years, median 33 years, range 18 to 61 years). The
presence and localization of kidney cysts as well as the ratio
of the signal intensity between medulla and cortex were deter-
mined.
Results. Fifty percent of the Fabry disease patients had re-
nal sinus cysts, compared to one individual (7%) in the control
group. The ratio of the signal intensity between medulla and cor-
tex on T2-weighted scans in Fabry disease patients with sinus
cysts was elevated compared with Fabry disease patients with-
out cysts (P = 0.0083), and elevated in Fabry disease patients
without cysts compared with normal controls without cysts
(P = 0.0173).
Conclusion. The finding of multiple renal sinus cysts in the
workup of a patient with kidney disease patient should strongly
suggest the consideration of Fabry disease in the differential
diagnosis. The cause of such cysts in Fabry disease remains to
be elaborated.
The rare X-linked lysosomal storage disorder Fabry
disease, OMIM 301500, is caused by the deficiency
1These authors contributed equally to this work.
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of ceramidetrihexosidase, commonly referred to as
alpha-galactosidase A (AGALA) [1]. The incidence is
estimated between 1:40,000 and 1:117,000 [2]. Globo-
triaosylceramide (Gb3), digalactosylceramide, blood
group B, B1, and P1 glycolipids are accumulated in a vari-
ety of different cell types, such as dorsal root ganglia neu-
ronal cells of the autonomic nervous system myocardial
cells, valvular fibroblasts, as well as vascular endothelial
cells, pericytes, and smooth muscle of the vascular system
[3–7].
In the kidney, Gb3 storage is found in numerous struc-
tures, such as glomerular epithelial cells (podocytes),
epithelial cells of Bowman’s capsule, mesangial cells, en-
dothelial cells of the glomerular capillary and glomerular
afferent arterioles, tubular epithelial cells, renal venules
and arteriols, epithelial cells of loops of Henle and dis-
tal tubules, as well as in the collecting ducts [8, 9]. Fabry
disease is a progressive debilitating disorder. Classically,
patients present a multitude of heterogeneous signs and
symptoms, such as angiokeratoma, edema, cornea verti-
cillata, hypohydrosis, neuropathic pain, cardiac hypertro-
phy, abdominal pain, diarrhea, fatigue, vertigo and stroke
[10, 11]. Kidney involvement can commence in adoles-
cence [12] and is expressed as a progressive spectrum
from normal to proteinuria to end-stage renal failure [13,
14]. In a study of 105 hemizygous patients, 50% of patients
had nonnephrotic range proteinuria and almost 20% had
early renal insufficiency [13]. Although heterozygous, fe-
males can also develop kidney disease [15] and end-stage
renal failure [16]. End-stage renal failure contributes sig-
nificantly to morbidity and mortality in Fabry disease.
In a recent analysis of the United States Renal Disease
System (USRDS) database conducted by Thadhani et al
[17], the mean age of patients with Fabry disease who
were started on dialysis between 1995 and 1998 in the
United states was 42 years; Twelve percent of these pa-
tients were females. The 3-year survival was 63% [17].
The mean age of initiation of dialysis in Fabry disease pa-
tients whose data were entered in the European Renal
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Table 1. Demographic and clinical characteristics of 24 hemizygous patients with Fabry disease
Residual
AGALA
Inulin Protein activity
Patient Age Kidney clearance excretion (% of normal
number years cysts mL/min mg/24 hours controls) Genotype
1 20 − 130 274 0 R356W
2 21 − 108 901 1.7 R227X
3 26 − 95 447 0.8 ins 24, del 4 ex 7
4 26 + 121 515 0.2 R356W
5 29 + 108 127 0.5 Q357X
6 29 − 83 1200 0.3 G144V
7 30 + 79 401 0.7 ND
8 32 − 33 1764 0.6 A143P
9 33 + 79 277 1.3 26 bp del 21
10 34 − 95 128 5.1 M51K
11 34 − 160 794 0.9 R227X
12 34 + 101 255 0.5 A1131G
13 35 + 88 315 2.0 K240X
14 38 + 83 374 0.5 W277X
15 39 − 71 3909 0.4 26 bp del 21
16 39 + 55 1530 0.3 N34S
17 40 + 56 7584 0.7 C142X
18 40 − 104 1029 1.3 Q250X
19 40 + 64 454 1.3 53 bp del 375 ms (−125)
20 43 − 119 84 8.3 A97V
21 44 + 79 180 0.6 W162X
22 46 − 51 2156 0.8 ND
23 46 − 102 207 0.7 H302X
24 49 + 50 284 0.7 D93X ms (−63) ex7
Abbreviations are: AGALA, alpha-galactosidase A; ND, not done.
Association–European Dialysis and Transplant Associa-
tion Registry until December 31, 1993 was 38 years, 12%
were females, and the 3-year survival was 60% [18].
The diagnosis of Fabry disease is usually made by
strong clinical suspicion and recognition of the overall
coherence of the multiple clinical findings; this is often ac-
celerated by a workup of a more specific finding, such as
angiokeratoma or corneal opacities [19]. Pedigree stud-
ies of affected families are of high value for identifying
affected individuals. However, patients are often diag-
nosed relatively late in the course of the disease as a con-
sequence of complications. A significant number of cases
are diagnosed by nephrologists [20]. In order to enhance
the identification of Fabry disease and to identify key
novel diagnostic features we conducted a cross-sectional
case control study of the morphologic renal abnormali-
ties by magnetic resonance imaging (MRI) and computed
tomography (CT).
METHODS
Patients
Twenty-four classically affected Fabry disease patients
with chronic neuropathic pain who were enrolled under
an Institutional Review Board approved study protocol
in an enzyme replacement trial [21] underwent prospec-
tive renal imaging evaluation with MRI and CT at the
Warren Magnuson Clinical Center of the National Insti-
tutes of Health, Bethesda, Maryland. The patients were
selected based on the presence of significant neuropathic
pain. All patients gave written informed consent. The pa-
tients’ mean age was 36.1 ± 8.1 years (median 37 years),
range 20 to 48 years. The diagnosis of Fabry disease was
confirmed by AGALA enzyme analysis in all patients.
Concurrently, we enrolled 19 age-matched healthy con-
trols (mean age 34.6 ± 12.0 years, median 33 years, range
18 to 61 years), who were recruited via the National Insti-
tutes of Health Study Volunteer Program. The age differ-
ence between both groups was not statistically significant
(Wilcoxon test; P = 0.18). The presence and localization
of kidney cysts as well as medulla to cortex signal inten-
sity ratio were analyzed by an experienced radiologist
who was blinded to the diagnosis.
MRI studies were performed with a General Electric
Medical Systems (GEMS, Milwaukee, WI, USA), 1.5 T
magnet equipped with enhanced gradient subsystems. All
patients were scanned with the body coil. The scan se-
ries were designed from the coronal plane to cover both
right and left kidneys. Scan series included T1-weighted
gradient echo (GRE) scans in the axial plane, with the
echo time (TE) in and out of phase as well as a T1-
weighted GRE, TE out of phase, coronal. Additional
scans included T2-weighted single-shot fast spin echo
with fat saturation (SS FSE), in the axial and coronal
planes. All images were obtained during breath-holding
at end respiration. Scan parameters for the T1-weighted
GRE scans were as follows: Body coil (36 cm × 0.75);
two-dimensional, spoiled gradient recalled echo [single
980 Ries and Bettis et al: Fabry parapelvic kidney cysts
proton gradient resonance (SPGR)]; repetition time
(TR) 150 msec; TE in and out of phase; flip angle 60◦;
bandwidth 32 kHz; slice thickness 7 mm skip 0; matrix 256
× 128; number of excitations (NEX) 1. Scan parameters
for the SS FSE were as follows: slice thickness was 7 mm
with skip of 0 mm; matrix 256 × 192; band-width 62.5 kHz;
TE 60; .5 NEX; respiratory compensation was applied.
All MR images were exported to an off-line workstation
(Sun Microsystems, Palo Alto, CA, USA) for postpro-
cessing and region-of-interest (ROI) analysis.
CT studies
CT scans were obtained on four and eight multide-
tector helical CT units (General Electric, Waukesha WI,
USA). Five millimeter collimation was employed using a
full body field of view (32 to 40 cm), 120 peak kilovoltage
(Kvp), and 150 to 300 milliampere seconds (mas). Intra-
venous contrast media was not employed. These scans
were obtained prior to CT-guided renal biopsies which
were part of the larger treatment protocol and thus the
CT scans were not obtained for research purposes alone.
Diagnostic criteria
Cysts were classified on MRI by the signal intensity of
their contents and their location. Criteria for a cyst in-
cluded low signal intensity on T1-weighted images and
very high signal intensity on T2-weighted images. The
determination of a parapelvic location was made when
the cyst abutted the collecting system which was visible
on T2-weighted images. Multiple cysts were present be-
fore parapelvic cysts were diagnosed. On CT, low density
(measuring less than 10 Hounsfield units) renal lesions
within the renal sinus were diagnostic of parapelvic cysts.
All patients with Fabry disease underwent kidney biop-
sies and a 24-hour urine collection was performed. Gb3
concentrations of the kidney tissue and the collected
urines were determined as described before [21].
Inulin clearance was used to estimate glomerular fil-
tration rate (GFR).
Statistics
Because of concern of violation of assumptions of para-
metric tests due to limited sample size, a conservative,
nonparametric approach was chosen using the Wilcoxon
test, two-sided with the significance level set at P < 0.05.
RESULTS
Twelve patients of the 24, mean age 36.3 ± 6.9 years
(median 37 years), range 26 to 48 years, had multiple renal
sinus cysts (Table 1) (Fig. 1A). Twelve patients, mean age
35.8 ± 9.6 years (median 36.5 years), range 20 to 48 years,
were free of parapelvic kidney cysts.
In the group of patients between 20 and 29 years of age,
33% had parapelvic kidney cysts; in the age group 30 to
A
B
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Fig. 1. Renal magnetic resonance imaging (MRI) and computed to-
mography (CT). Row 1 denotes T1-weighted gradient echo coronal out
of phase, row 2 denotes T2-weighted coronal single-shot fast spin echo
with fat saturation, and row 3 denotes axial CT scan. (A) Patients with
Fabry disease with peripelvic cysts. From left to right: patient 12, pa-
tient 5, and patient 7. (B) From left to right: healthy control without
peripelvic cysts, healthy control with peripelvic cysts, and patient with
Fabry disease without peripelvic cysts (patient 10). To avoid unneces-
sary radiation exposure, controls did not undergo a CT evaluation. (C)
Sagittal ultrasound demonstrates multiple hypoechoic parapelvic cysts
in patients with Fabry disease. Left, patient 5; right, patient 7.
39 years of age, 60%, and in the group 40 to 49 years of
age, 50% of the patients exhibited this finding (Fig. 2).
In the control group of 19 healthy volunteers, we de-
tected one individual (age 61 years) with parapelvic kid-
ney cysts (Fig. 1B). This subject was asymptomatic with no
history of renal problems. A biopsy was not performed.
Although not part of this research protocol, some pa-
tients with Fabry disease had renal ultrasound examina-
tions. Parapelvic kidney cysts were readily visualized by
this procedure (Fig. 1C).
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Table 2. Renal parameters and magnetic resonance imaging (MRI) findings in the Fabry disease patients and controls
Fabry disease Healthy controls
No cysts Cysts No cysts Cysts
(N = 12) (N = 12) (N = 18) (N = 1)
Age years mean (median) 35.8 (36.5) 36.3 (37) 33.1 (32) 61
SD (minimum . . . maximum) 9.6 (20 . . . 48) 6.9 (26 . . . 48) 10.4 (18 . . . 61)
Residual AGALA activity % of normal controls
mean (median)
1.7 (0.8) 0.8 (0.7)
SD (minimum . . . maximum) 2.5 (0 . . . 8.3) 0.5 (0.2 . . . 2)
Inulin clearance mL/min mean (median) 95.9 (98.5) 80.3 (79.0)
SD (minimum . . . maximum) 34.1 (33 . . . 160) 22.0 (50 . . . 121)
Urinary Gb3 excretion nmol/mg creatinine mean
(median)
2299 (2359.50) 2466 (2178)
SD (minimum . . . maximum) 1308.9 (81 . . . 4824) 1439.0 (583 . . . 4990)
Renal Gb3 content nmol/mg tissue mean (median) 19.0 (18.8) 19.1 (N = 10) (17.3)
SD (minimum . . . maximum) 9.6 (0.7 . . . 38) 6.0 (13.5 . . . 31.5)
24-hour urine protein excretion mg mean (median) 1058 (847) 1030 (345)
SD (minimum . . . maximum) 1090 (84 . . . 3909) 2055 (127 . . . 7584)
SIRmedulla/cortex mean (median) 1.18a,b (1.14) 1.47a(1.46) 1.10b (N = 13) (1.10) 1.14
SD (minimum . . . maximum) 0.11 (1.03 . . . 1.46) 0.25 (1.08 . . .. 1.83) 0.06 (1.02 . . . 1.23)
Abbreviations are: AGALA, alpha-galactosidase A; Gb3, globotriaosylceramide; SIR, signal intensity ratio.
aP = 0.0083, bP = 0.0173 (Wilcoxon test).
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Fig. 2. Percentage of patients with Fabry disease with kidney cysts by
decade (N = 24).
There were no statistically significant differences
in age, residual AGALA activity, kidney function as
assessed by inulin clearance, Gb3 of the kidney tissue
and urine, as well as protein excretion between the Fabry
disease group with kidney cysts compared with the Fabry
disease group without kidney cysts and compared with
controls (Tables 1 and 2). The ratio of the signal intensity
(SIR) between medulla and cortex on T2-weighted scans
in Fabry disease patients with sinus cysts was elevated
compared with Fabry disease patients without cysts (P =
0.0083), and elevated in Fabry disease patients without
cysts compared with normal controls without cysts (P =
0.0173).
DISCUSSION
In this cohort of classically affected patients with Fabry
disease, we found a surprisingly high prevalence of renal
sinus or parapelvic cysts (50%), of variable size, with a dis-
tinct appearance compared with healthy controls (7%).
The prevalence of these cysts was lower in the patients
between 20 and 29 years of age than in those between 30
and 39 as well as 40 to 49 years of age.
Parapelvic cysts can be confused with hydronephrosis
leading to unnecessary workups. Solitary or simple cysts,
localized in cortex or medulla, are commonly found in-
cidentally [22] in 5.8% to 10% of males and increase in
frequency with age [23]. Renal sinus cysts, however, were
reported to occur in between 1.28% of the older popu-
lation [24], 1.5% [25], or 6% [26]; their frequency in the
general population assessed with the MRI method used
in this present study has not been determined.
Kidney cysts occur as distinctive genetic disorders or
in association with inherited or acquired kidney patholo-
gies (e.g., multiple sponge kidney lesions in medulla and
papilla, or autosomal and recessive medullary cystic kid-
ney disease). Other disease entities that are associated
with liver disease are autosomal-dominant polycystic kid-
ney disease (ADPKD) or autosomal-recessive polycystic
kidney disease (ARPKD). The prevalence of ADPKD
is estimated to be between 1:500 and 1:1000, the reces-
sive form ARPKD occurs in a frequency of 1:16,000 [22].
However, all of these cysts involve the renal parenchyma.
To our knowledge, there are no genetic entities with a pre-
disposition to the formation of sinus or parapelvic cysts
other than Fabry disease.
The renal sinus, surrounded by the collecting system of
the kidney, contains lymphatic vessels, nerves, and other
vascular structures enclosed by fibrous and fatty tissue.
Keyl, Bell, and Parry [27] showed that occlusion of sinus
lymphatics resulted in rapid proximal dilatation of the
sinus lymphatics. However, the etiology and exact mech-
anism of sinus cyst formation in Fabry disease remains
to be elucidated. Cysts and pseudocysts were observed
in other parts of the body of Fabry disease patients, such
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as the maxillary sinus [28]. Patients with ADPKD have
a relatively high rate of cardiac valvular abnormalities
(i.e., mitral valve regurgitation [22]), which has also been
observed in Fabry disease [29], where glycolipid accumu-
lation was described in vascular endothelium and heart
valves [30]. Patients with Fabry disease also often have
cardiac problems, such as cardiomyopathy and cardiac
conduction defects [31].
The quantitative differences in signal intensity between
the medulla and the cortex measured in this study were
statistically significant. Although the clinical significance
of this finding is uncertain at this time, it may represent
a marked difference in water or Gb3 content. Follow-up
in patients receiving enzyme replacement therapy will be
important.
The present paper is limited by the relatively small
number of patients and controls. Only classically affected
hemizygous patients with Fabry disease were included,
we therefore cannot provide information about heterozy-
gous patients and those with attenuated phenotypes.
Whether the formation of cysts in Fabry disease is due
to storage of lipids, altered local metabolism, or genetic
regulatory processes remains unknown; we could not find
any published autopsy report of Fabry disease that de-
scribes cysts of the kidney, so that the precise nature of
these cysts remains undefined.
The group of patients with Fabry disease had a high
prevalence of detectable proteinuria. The finding of mul-
tiple renal sinus cysts in the workup of a kidney disease
patient should strongly suggest the differential diagnosis
of Fabry disease in the appropriate clinical setting. Ul-
trasound is useful in the further workup. There is, how-
ever, the need for a high index of suspicion in individuals
with a positive family history or other stigmata of the
disease, such as angiokeratoma, dilated tortuous retinal
blood vessels, corneal and lenticular opacities. Establish-
ing the correct diagnosis is especially important given the
availability of an enzyme replacement therapy for Fabry
disease.
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